- May 3, 2022– Webcast to be Held at 8:00 am ET on May 10, 2022 – NEW YORK, May 3, 2022 – Immunic,…
- April 25, 2022NEW YORK, April 25, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- March 16, 2022NEW YORK, March 16, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- March 8, 2022NEW YORK, March 8, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- February 24, 2022– Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort…
- February 18, 2022– Top-Line Data of the CALDOSE-1 Trial Expected to be Available in June of 2022 – NEW YORK, February 18,…
- February 17, 2022– Webcast to be Held at 8:00 am ET on February 24, 2022 – NEW YORK, February 17, 2022 – Immunic,…
- February 8, 2022NEW YORK, February 8, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- February 2, 2022NEW YORK, February 2, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
